1.Schweitzer, A et al. (2015) Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386, 1546–1555.
2.Hatzakis, A et al. (2011) The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. Journal of Viral Hepatitis 18(suppl. 1), 1–16.
3.Lampertico, P, Maini, M and Papatheodoridis, G (2015) Optimal management of hepatitis B virus infection – EASL special conference. Journal of Hepatology 63, 1238–1253.
4.McMahon, B et al. (2016) Hepatitis-Associated liver cancer: gaps and opportunities to improve care. Journal of the National Cancer Institute 108, djv359.
6.World Health Organization (2017) Guidelines on Hepatitis B and C Testing. Geneva, Switzerland: World Health Organization.
7.Spenatto, N et al. (2013) Hepatitis B screening: who to target? A French sexually transmitted infection clinic experience. Journal of Hepatology 58, 690–697.
8.Veldhuijzen, IK et al. (2012) Identification and treatment of chronic hepatitis B in Chinese migrants: results of a project offering on-site testing in Rotterdam, The Netherlands. Journal of Hepatology 57, 1171–1176.
9.Zhou, K et al. (2016) Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infectious Diseases 16, 1409–1422.
10.Bottero, J et al. (2013) Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. Journal of Hepatology 58, 473–478.
11.Pioche, C et al. (2018) Dépistage des hépatites B et C en France en 2016, nouvelle édition de l'enquête LaboHep [Hepatitis B and C screening in France in 2016. The New edition of the LaboHep study]. Bulletin epidémiologique hebdomadaire 11, 188–195. French.
12.Bottero, J et al. (2016) French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. Liver International 36, 1442–1449.
13.LeFevre, ML (2014) U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 161, 58–66.
14.Topp, L et al. (2009) Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: a review. Drug & Alcohol Review 28, 669–675.
15.Brouard, C et al. (2017) Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011–2013. Epidemiology & Infection 145, 1259–1269.
16.Nielsen, US et al. (2015) Hepatitis B infection and vaccination coverage in men who have sex with men consulting a Danish venereal disease clinic. Infectious Diseases 47, 517–522.
17.Pitasi, MA et al. (2014) Hepatitis B virus (HBV) infection, immunity and susceptibility among men who have sex with men (MSM), Los Angeles County, USA. AIDS & Behavior 18(suppl. 3), 248–255.
18.Legoupil, C et al. (2017) Out-of-Hospital screening for HIV, HBV, HCV and Syphilis in a vulnerable population, a public health challenge. AIDS Care 29, 686–688.
19.Boyd, A et al. (2017) Testing for hepatitis B virus alone does not increase vaccine coverage in non-immunized persons. World Journal of Gastroenterology 23, 7037–7046.
20.de la Fuente, L et al. (2007) Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy ‘don't ask, draw a blood sample, vaccinate and try to schedule another visit.’ Journal of Clinical Virology 38(1), 87–90.
21.Kuo, I et al. (2004) Poor validity of self-reported hepatitis B virus infection and vaccination status among young drug users. Clinical Infectious Diseases 38, 587–590.
22.Thornton, L et al. (2000) Comparison between self-reported hepatitis B, hepatitis C, and HIV antibody status and oral fluid assay results in Irish prisoners. Communicable Disease and Public Health 3, 253–255.
23.Origer, A and Schmit, J-C (2012) Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg: self-report versus serological evidence. Journal of Epidemiology & Community Health 66, 64–68.
24.Pioche, C et al. Indicateurs régionaux de dépistage et de prévalence des hépatites B et C. France 2010–2012 [Regional indicators of testing and prevalence for hepatitis B and C France 2010–2012]. Institut Veille Sanitaire [Internet]. 2014. [cited 2018 Sept 2]. Available at http://www.invs.sante.fr. French.
25.Fishbein, DB et al. (2006) Determining indications for adult vaccination: patient self-assessment, medical record, or both? Vaccine 24, 803–818.
26.Brouard, C et al. (2013) Hepatitis B knowledge, perceptions and practices in the French general population: the room for improvement. BMC Public Health 13, 576.
27.Upadhyaya, N et al. (2010) Chronic hepatitis B: perceptions in Asian American communities and diagnosis and management practices among primary care physicians. Postgraduate Medicine 122, 165–175.
28.Girard, A et al. (2010) Analysis of medical prescribing practices for hepatitis B serology tests. Gastroentérologie clinique et biologique 34, 8–15.
29.Chen, MS et al. (2013) Increasing hepatitis B screening for hmong adults: results from a randomized controlled community-based study. Cancer Epidemiology, Biomarkers & Prevention 22, 782–791.
30.Zacharias, T et al. (2015) HBV outreach programs significantly increase knowledge and vaccination rates among Asian pacific islanders. Journal of Community Health 40, 619–624.
31.Bruce, MG et al. (2016) Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. Journal of Infectious Diseases 214, 16–22.
32.Wilson, JN et al. (2007) Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules. Vaccine 25, 3705–3712.
33.Walayat, S et al. (2015) Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World Journal of Hepatology 7, 2503–2509.
34.Wang, Q, Klenerman, P and Semmo, N (2017) Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterology & Hepatology 2, 123–134.
35.Bottero, J et al. (2016) Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study. European Journal of Gastroenterology & Hepatology 28, 633–639.
36.Bottero, J et al. (2015) Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-to-care: results of a randomized control trial in persons without healthcare coverage. Open Forum Infectious Diseases 2, ofv162.
37.Perumalswami, PV et al. (2013) Hepatitis outreach network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. Journal of Hepatology 58, 890–897.
38.Tedder, RS et al. (2013) The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. Clinical Infectious Diseases 56, 951–960.
39.European Association for the Study of the Liver (2017) European association for the study of the liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. Journal of Hepatology 67, 370–398.
40.Loomba, R and Liang, TJ (2017) Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 152, 1297–1309.